Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors

ABSTRACT Tenofovir alafenamide fumarate (TAF) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV). Previous studies suggested a principal role for the lysosomal serine protease cathepsin A (CatA) in the intracellular activation of TAF. Here we further investigated the role of CatA and other human hydrolases in the metabolism of TAF. Overexpression of CatA or liver carboxylesterase 1 (Ces1) in HEK293T cells increased intracellular TAF hydrolysis 2- and 5-fold, respectively. Knockdown of CatA expression with RNA interference (RNAi) in HeLa cells reduced intracellular TAF metabolism 5-fold. Additionally, the anti-HIV activity and the rate of CatA hydrolysis showed good correlation within a large set of TFV phosphonoamidate prodrugs. The covalent hepatitis C virus (HCV) protease inhibitors (PIs) telaprevir and boceprevir potently inhibited CatA-mediated TAF activation (50% inhibitory concentration [IC50] = 0.27 and 0.16 μM, respectively) in vitro and also reduced its anti-HIV activity in primary human CD4+ T lymphocytes (21- and 3-fold, respectively) at pharmacologically relevant concentrations. In contrast, there was no inhibition of CatA or any significant effect on anti-HIV activity of TAF observed with cobicistat, noncovalent HIV and HCV PIs, or various prescribed inhibitors of host serine proteases. Collectively, these studies confirm that CatA plays a pivotal role in the intracellular metabolism of TAF, whereas the liver esterase Ces1 likely contributes to the hepatic activation of TAF. Moreover, this work demonstrates that a wide range of viral and host PIs, with the exception of telaprevir and boceprevir, do not interfere with the antiretroviral activity of TAF.

[1]  D. Podzamczer,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials , 2015, The Lancet.

[2]  A. Ray,et al.  Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy , 2015, Antimicrobial Agents and Chemotherapy.

[3]  John F. Flaherty,et al.  Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. , 2015, Journal of hepatology.

[4]  S. Yant,et al.  Metabolism and Antiretroviral Activity of Tenofovir Alafenamide in CD4+ T-Cells and Macrophages from Demographically Diverse Donors , 2014, Antiviral therapy.

[5]  P. Sax,et al.  Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study , 2014, Journal of acquired immune deficiency syndromes.

[6]  U. Bredeek,et al.  Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults , 2013, Journal of acquired immune deficiency syndromes.

[7]  J. Kilby.  Faculty Opinions recommendation of Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide (TAF) as 10-day monotherapy in HIV-1-positive adults. , 2013 .

[8]  M. Sofia.  Nucleotide prodrugs for the treatment of HCV infection. , 2013, Advances in pharmacology.

[9]  Anil Kumar.  Tenofovir Disoproxil Fumarate , 2012, Drugs.

[10]  K. Hostetler,et al.  Application of kinase bypass strategies to nucleoside antivirals. , 2011, Antiviral research.

[11]  T. Chou,et al.  Role of Cathepsin A and Lysosomes in the Intracellular Activation of Novel Antipapillomavirus Agent GS-9191 , 2011, Antimicrobial Agents and Chemotherapy.

[12]  M. Otto,et al.  Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 , 2010, The Journal of Biological Chemistry.

[13]  William A. Lee,et al.  GS-9191 Is a Novel Topical Prodrug of the Nucleotide Analog 9-(2-Phosphonylmethoxyethyl)Guanine with Antiproliferative Activity and Possible Utility in the Treatment of Human Papillomavirus Lesions , 2009, Antimicrobial Agents and Chemotherapy.

[14]  R. Geleziunas,et al.  Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase , 2008, Antimicrobial Agents and Chemotherapy.

[15]  William A. Lee,et al.  Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and Other Tenofovir Phosphonoamidate Prodrugs by Human Proteases , 2008, Molecular Pharmacology.

[16]  A. Lok,et al.  Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. , 2008, Journal of hepatology.

[17]  K. White,et al.  Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131 , 2007, Antimicrobial Agents and Chemotherapy.

[18]  William A. Lee,et al.  Cathepsin A Is the Major Hydrolase Catalyzing the Intracellular Hydrolysis of the Antiretroviral Nucleotide Phosphonoamidate Prodrugs GS-7340 and GS-9131 , 2006, Antimicrobial Agents and Chemotherapy.

[19]  N. Butkiewicz,et al.  SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.

[20]  A. Kwong,et al.  Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease , 2006, Antimicrobial Agents and Chemotherapy.

[21]  Teruko Imai,et al.  Human carboxylesterase isozymes: catalytic properties and rational drug design. , 2006, Drug metabolism and pharmacokinetics.

[22]  William A. Lee,et al.  Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue , 2005, Antimicrobial Agents and Chemotherapy.

[23]  B. Eriksson,et al.  Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement , 2005, Journal of clinical pharmacology.

[24]  J. Rodman,et al.  Metabolism of Tenofovir and Didanosine in Quiescent or Stimulated Human Peripheral Blood Mononuclear Cells , 2003, Pharmacotherapy.

[25]  J. Kahn,et al.  Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults , 2001, Antimicrobial Agents and Chemotherapy.

[26]  William A. Lee,et al.  NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 1091–1098 (2001) METABOLISM OF GS-7340, A NOVEL PHENYL MONOPHOSPHORAMIDATE INTRACELLULAR PRODRUG OF PMPA, IN BLOOD , 2003 .

[27]  A. Pshezhetsky,et al.  Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology. , 2001, Progress in nucleic acid research and molecular biology.

[28]  S. Swan,et al.  The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal Dysfunction , 2000, Pharmacotherapy.

[29]  Z. Suo,et al.  Selective Inhibition of HIV-1 Reverse Transcriptase by an Antiviral Inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine* , 1998, The Journal of Biological Chemistry.

[30]  E. De Clercq,et al.  Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. la Colla,et al.  Decomposition pathways and in vitro HIV inhibitory effects of isoddA pronucleotides: toward a rational approach for intracellular delivery of nucleoside 5'-monophosphates. , 1996, Journal of medicinal chemistry.

[32]  C. Mcguigan,et al.  Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT): potent activity of the trichloroethyl methoxyalaninyl compound. , 1991, Antiviral research.

[33]  D. Jeffries,et al.  Synthesis and anti-HIV Activity of Some Novel Phosphorodiamidate Derivatives of 3′-azido-3′-deoxythymidine (AZT) , 1991 .

[34]  Christopher McGuigan,et al.  Attempts to introduce chemotherapeutic nucleotides into cells: studies on the anti-HIV agent FDT , 1991 .

[35]  E. De Clercq,et al.  Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro. , 1990, Biochemical pharmacology.

[36]  R. Skidgel,et al.  A peptidase in human platelets that deamidates tachykinins. Probable identity with the lysosomal "protective protein". , 1990, The Journal of biological chemistry.

[37]  M. Potier,et al.  Deficient lysosomal carboxypeptidase activity in galactosialidosis. , 1990, Biochemical and biophysical research communications.

[38]  C. Mcguigan,et al.  Novel phosphate derivatives of zidovudine as anti-HIV compounds. , 1990, AIDS.

[39]  H. Galjaard,et al.  Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man. , 1982, Proceedings of the National Academy of Sciences of the United States of America.